Search results for "RAV"

showing 10 items of 5866 documents

A unique fatal case of Waterhouse–Friderichsen syndrome caused by Proteus mirabilis in an immunocompetent subject

2019

Abstract Introduction: The Waterhouse–Friderichsen syndrome (WFS), also known as purpura fulminans, is a potentially lethal condition described as acute hemorrhagic necrosis of the adrenal glands. It is often caused by infection. Classically, Neisseriae meningitidis represents the main microorganism related to WFS, although, infrequently, also other infectious agents are reported as a possible etiologic agent. The authors report the first case of death due to Proteus mirabilis infection, with postmortem evidence of WFS. Patient concerns: After a facial trauma that provoked a wound on the nose, the subject, a healthy 40-years old man, was conducted to the local hospital (in Sicily, Italy) af…

AdultMalemedicine.medical_specialtySepsiforensic sciencesAutopsyGastroenterologysepsisSepsisImmunocompromised Host03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleInternal medicinemedicineWaterhouse–Friderichsen syndromeHumansClinical Case Report030212 general & internal medicineLeukocytosisProteus mirabilisWaterhouse-Friderichsen syndromeDisseminated intravascular coagulationbiology4900business.industryBilateral massive adrenal hemorrhageWaterhouse-Friderichsen syndrome: XGeneral Medicinemedicine.diseasebiology.organism_classificationProteus InfectionProteus mirabilisBilateral massive adrenal hemorrhage; Forensic sciences; Proteus mirabilis infection; Sepsis; Waterhouse-Friderichsen syndrome; Adult; Humans; Male; Proteus Infections; Waterhouse-Friderichsen Syndrome; Immunocompromised Host; Proteus mirabilisProteus mirabilis infection030220 oncology & carcinogenesisForensic sciencemedicine.symptomProteus InfectionsbusinessAdrenal HemorrhageResearch ArticleHumanPurpura fulminansMedicine
researchProduct

High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease.

2018

AbstractContextSerum TSH receptor autoantibody (TSH-R-Ab) is a biomarker of Graves disease (GD). Studies have shown that the levels of this TSH-R-Ab have clinical significance.ObjectiveTo differentiate between thyroidal GD only and Graves orbitopathy (GD + GO).DesignControlled, follow-up study.SettingAcademic tertiary referral center for GD + GO.SubjectsSixty patients with GD, GD + GO, and controls.InterventionSerial serum dilution analyses with six automated, ELISA, and cell-based assays for TSH-R-Ab.Main Outcome MeasureDifferentiation among GD phenotypes.ResultsAll undiluted samples of hyperthyroid-untreated GD patients were positive with the six assays but became negative at dilution 1:9…

AdultMalemedicine.medical_specialtySerial dilutionEndocrinology Diabetes and MetabolismGraves' diseaseClinical Biochemistry030209 endocrinology & metabolismContext (language use)BiochemistryThyrotropin receptorDiagnosis Differential03 medical and health sciencesYoung Adult0302 clinical medicineEndocrinologyAntithyroid AgentsInternal medicineMedicineHumansEuthyroidAgedAutoantibodiesMethimazolebiologybusiness.industryBiochemistry (medical)AutoantibodyReceptors ThyrotropinMiddle Agedmedicine.diseasePrognosisGraves DiseaseGraves OphthalmopathyTiterEndocrinology030220 oncology & carcinogenesisbiology.proteinFemaleAntibodybusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

Cataracts and statins. A disproportionality analysis using data from VigiBase.

2019

The basis of the association between statin use and cataract has been explored using the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) through January 2019. The reporting odds ratios (RORs) as a measure of disproportionality for reported cataracts and individual statins have been calculated. Subgroup analyses according statin lipophilicity, sex, and age groups have been performed. Moreover, RORs have been calculated for non-statin lipid lowering drugs. An increased disproportionality have been found for most individual statins lovastatin: [ROR: 14.80, 95% confidence interval (CI): 13.30, 16.46)], atorvastatin (ROR: 3…

AdultMalemedicine.medical_specialtyStatinAdolescentmedicine.drug_classAtorvastatin010501 environmental sciencesToxicology030226 pharmacology & pharmacy01 natural sciencesRisk AssessmentCataract03 medical and health sciencesPharmacovigilanceYoung Adult0302 clinical medicineEzetimibeInternal medicinemedicineOdds RatioAdverse Drug Reaction Reporting SystemsHumansRosuvastatinChild0105 earth and related environmental sciencesAgedAged 80 and overbusiness.industryIncidenceGeneral MedicineOdds ratioMiddle AgedSimvastatinFemaleDrug MonitoringHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatinRegulatory toxicology and pharmacology : RTP
researchProduct

Pravastatin reverses the membrane cholesterol reorganization induced by myocardial infarction within lipid rafts in CD14(+)/CD16(-) circulating monoc…

2012

International audience; Large numbers of monocytes are recruited in the infarcted myocardium. Their cell membranes contain cholesterol-rich microdomains called lipids rafts, which participate in numerous signaling cascades. In addition to its cholesterol-lowering effect, pravastatin has several pleiotropic effects and is widely used as secondary prevention treatment after myocardial infarction (MI). The aim of this study was to investigate the effects of pravastatin on the organization of cholesterol within monocyte membrane rafts from patients who had suffered myocardial infarction. Monocytes from healthy donors and acute MI patients were cultured with or without 4μM pravastatin. Lipid raf…

AdultMalemedicine.medical_specialtyStatinmedicine.drug_classCD14[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionCaveolin 1Lipopolysaccharide Receptors030204 cardiovascular system & hematologyCD16GPI-Linked ProteinsMonocytes03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCaveolaeInternal medicinemedicineHumansMolecular BiologyLipid raftCells Cultured030304 developmental biologyPravastatin0303 health sciencesCholesterolMonocyteAnticholesteremic AgentsReceptors IgGstatinCell BiologyMiddle Aged3. Good healthlipid raftEndocrinologymedicine.anatomical_structureCholesterolmyocardial infarctionchemistryGene Expression RegulationImmunologycaveolaemonocyteFemalelipids (amino acids peptides and proteins)[SDV.AEN]Life Sciences [q-bio]/Food and NutritionPravastatinmedicine.drug
researchProduct

The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis

2009

Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) inhibits T-cell activation and interleukin-2 (IL-2) production. The PTPN22(gain-of-function)+1858T(+) genotypes predispose to multiple autoimmune diseases, including early-onset (non-thymomatous) myasthenia gravis (MG). The disease association and the requirement of IL-2/IL-2 receptor signaling for intrathymic, negative T-cell selection have suggested that these genotypes may weaken T-cell receptor (TCR) signaling and impair the deletion of autoreactive T cells. Evidence for this hypothesis is missing. Thymoma-associated MG, which depends on intratumorous generation and export of mature autoreactive CD4(+) T cells, is a model of au…

AdultMalemedicine.medical_specialtyThymomaAdolescentGenotypeThymomaImmunologyBiologymedicine.disease_causePolymorphism Single NucleotideWhite PeopleAutoimmunityPTPN22Young AdultAntigens CDInternal medicineMyasthenia GravisCentral tolerance inductionGeneticsmedicineHumansCTLA-4 AntigenGenetic Predisposition to DiseaseReceptorGenetics (clinical)AgedAged 80 and overT-cell receptorProtein Tyrosine Phosphatase Non-Receptor Type 22Thymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyInterleukin-2FemaleCentral toleranceGenes & Immunity
researchProduct

Total Versus Near-total Thyroidectomy in Graves Disease

2019

Previous data suggest that the incidence of hypoparathyroidism after surgery for Graves disease (GD) is lower after subtotal thyroidectomy compared to total thyroidectomy (TT). The present study evaluated the incidence of postoperative hypoparathyroidism after near-total (NTT) versus TT in GD.In a multicenter prospective randomized controlled clinical trial, patients with GD were randomized intraoperatively to NTT or TT. Primary endpoint was the incidence of transient postoperative hypoparathyroidism. Secondary endpoints were permanent hypoparathyroidism, transient recurrent laryngeal nerve palsy (RLNP), reoperations for bleeding, inadvertently removed parathyroid glands, and recurrent hype…

AdultMalemedicine.medical_specialtyTime FactorsHypoparathyroidismGraves' diseaseRisk AssessmentSeverity of Illness IndexTransplantation Autologouslaw.inventionParathyroid GlandsYoung Adult03 medical and health sciencesPostoperative Complications0302 clinical medicineRandomized controlled triallawSeverity of illnessmedicineHumansProspective StudiesProspective cohort studybusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseaseGraves DiseaseSurgeryTransplantationNear total thyroidectomyTreatment OutcomeHypoparathyroidism030220 oncology & carcinogenesisThyroidectomyFemale030211 gastroenterology & hepatologySurgerybusinessFollow-Up StudiesAnnals of Surgery
researchProduct

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

2006

Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a prostacyclin analogue, used, according to a new protocol, in patients with Raynaud’s phenomenon secondary to Systemic Sclerosis. Methods: in this randomized study we treated 30 patients with Iloprost given by intravenous infusion, at progressively increasing doses (starting from 0.5 ng/Kg/min up 2 ng/Kg/min) over a period of 6 hours a day for ten days in two consecutive weeks, with repeated cycles at regular intervals of three months for 18 months. The results were compared with those obtained in 30 other patients, who had received the same drug but with different posologic schemes. Results: …

AdultMalemedicine.medical_specialtyTime FactorsVasodilator AgentsSeverity of Illness IndexDrug Administration ScheduleSclerodermalaw.inventionRheumatologyRandomized controlled trialQuality of lifelawSeverity of illnessmedicineHumansPharmacology (medical)IloprostProspective StudiesDosingInfusions IntravenousProspective cohort studySystemic Sclerosis Raynaud's phenomenon Iloprost Quality of lifeScleroderma SystemicDose-Response Relationship DrugVascular diseasebusiness.industryRaynaud DiseaseMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaQuality of LifeFemalebusinessIloprostmedicine.drugRheumatology
researchProduct

Intratympanic Dexamethasone/Hyaluronic Acid Mix as an Adjunct to Intravenous Steroid and Vasoactive Treatment in Patients With Severe Idiopathic Sudd…

2011

To evaluate differences in effectiveness (hearing recovery rates) between idiopathic sudden sensorineural hearing loss (ISSNHL) patients treated with intravenous therapy alone and patients treated with a combination of intravenous and intratympanic therapy.Retrospective case review.Tertiary referral hospital center.Ninety-four patients with moderate ISSNHL treated with an intravenous steroid and vasoactive regimen (duration of therapy, 9 ± 2.76 d) and 76 patients with severe ISSNHL treated with a combination regimen of intravenous and intratympanic therapy (duration of therapy, 10 ± 2.71 d) were reviewed. In the latter patients' group, a series of 3 intratympanic injections of a dexamethaso…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss Sensorineuralmedicine.medical_treatmentIntratympanic dexamethasoneDexamethasoneInjectionsSteroidchemistry.chemical_compoundVasoactiveInternal medicineHyaluronic acidotorhinolaryngologic diseasesmedicineHumansIn patientHyaluronic AcidGlucocorticoidsRetrospective Studiesbusiness.industryHearing Loss SuddenSensory SystemsHearing recoveryTreatment OutcomeEndocrinologyOtorhinolaryngologychemistryIntravenous therapyAnesthesiaSudden sensorineural hearing lossInjections IntravenousAudiometry Pure-ToneFemaleSteroidsNeurology (clinical)businessOtology & Neurotology
researchProduct

Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials

2015

Statin therapy may lower plasma coenzyme Q10 (CoQ10) concentrations, but the evidence as to the significance of this effect is unclear. We assessed the impact of statin therapy on plasma CoQ10 concentrations through the meta-analysis of available RCTs. The literature search included selected databases up to April 30, 2015. The meta-analysis was performed using either a fixed-effects or random-effect model according to I(2) statistic. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). The data from 8 placebo-controlled treatment arms suggested a significant reduction in plasma CoQ10 concentrations following treatment with statins (WMD: -0.44 μmol/…

AdultMalemedicine.medical_specialtyUbiquinoneAtorvastatinPharmacologyPlaceboGastroenterologychemistry.chemical_compoundDouble-Blind MethodInternal medicineHumansMedicineRosuvastatinClinical significanceAgedRandomized Controlled Trials as TopicPharmacologyCoenzyme Q10business.industryMiddle AgedPlacebo EffectConfidence intervalchemistrySimvastatinCase-Control StudiesFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugPharmacological Research
researchProduct

Pharmacokinetics of atenolol in relation to renal function

1981

The plasma levels and urinary excretion of carteolol and its main metabolites 8-hydroxycarteolol and carteolol glucuronide were investigated in 6 healthy subjects and 9 patients with varying degrees of renal impairment following a single oral dose of 30 mg carteolol hydrochloride. In healthy subjects the half-life of carteolol was 7.1 h. 63% of the administered dose was recovered unchanged in urine, and in all 84% was excreted by the kidneys. The renal clearance of carteolol was 255 ml/min. In chronic renal failure (CRF) the terminal half-life was increased to a maximum of 41 h. Both the elimination rate constant and renal clearance were closely related to the creatinine clearance. In CRF t…

AdultMalemedicine.medical_specialtyUrologyAdministration OralRenal functionCarteolol HydrochloridePropanolamineschemistry.chemical_compoundPharmacokineticsElimination rate constantRenal DialysisInternal medicinemedicineHumansPharmacology (medical)CarteololAgedPharmacologyKidneyCreatinineMaintenance dosebusiness.industryGeneral MedicineMiddle AgedKineticsEndocrinologymedicine.anatomical_structureAtenololchemistryInjections IntravenousFemaleKidney DiseasesbusinessGlomerular Filtration Ratemedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct